109 related articles for article (PubMed ID: 21538429)
21. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
Gholam PM
N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15570682
[No Abstract] [Full Text] [Related]
22. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
Zeuzem S
J Hepatol; 2008 Aug; 49(2):157-9. PubMed ID: 18554745
[No Abstract] [Full Text] [Related]
23. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
[TBL] [Abstract][Full Text] [Related]
24. [Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
Szalay F
Orv Hetil; 2010 Feb; 151(7):271-3. PubMed ID: 20133247
[No Abstract] [Full Text] [Related]
25. Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.
Villa E; Cammà C; Di Leo A; Karampatou A; Enea M; Gitto S; Bernabucci V; Losi L; De Maria N; Lei B; Ferrari A; Vukotic R; Vignoli P; Rendina M; Francavilla A
J Viral Hepat; 2012 Sep; 19(9):640-9. PubMed ID: 22863268
[TBL] [Abstract][Full Text] [Related]
26. Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!".
Baiocchi L; Lenci I; Carbone M; Angelico M
Hepatology; 2009 Nov; 50(5):1676-7. PubMed ID: 19876945
[No Abstract] [Full Text] [Related]
27. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study.
Witthoeft T; Hueppe D; John C; Goelz J; Heyne R; Moeller B; Teuber G; Wollschlaeger S; Baumgarten A; Simon KG; Moog G; Dikopoulos N; Mauss S
J Viral Hepat; 2010 Jul; 17(7):459-68. PubMed ID: 20158603
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of chronic hepatitis C].
Fehér J; Lengyel G
Orv Hetil; 2004 May; 145(20):1065-7. PubMed ID: 15202329
[No Abstract] [Full Text] [Related]
29. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
30. Peginterferon α-2a and rivabirin in the treatment of chronic hepatitis C.
Rahman MZ; Perveen S; Mahmuduzzaman M; Rahman MA; Chowdhury MS; Huda MN; Ahmed DS; Raihan MA
Mymensingh Med J; 2014 Apr; 23(2):335-40. PubMed ID: 24858163
[TBL] [Abstract][Full Text] [Related]
31. Compare trial: updated data.
Silva MO
J Hepatol; 2008 Aug; 49(2):288-9. PubMed ID: 18571269
[No Abstract] [Full Text] [Related]
32. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
34. Peginterferon alfa-2a in patients with chronic hepatitis C.
Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
[TBL] [Abstract][Full Text] [Related]
35. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a.
Sarrazin C; Hendricks DA; Sedarati F; Zeuzem S
J Clin Microbiol; 2001 Aug; 39(8):2850-5. PubMed ID: 11474002
[TBL] [Abstract][Full Text] [Related]
36. Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C.
Bruno R; Sacchi P; Maiocchi L; Zocchetti C; Ciappina V; Patruno S; Filice G
Antivir Ther; 2005; 10(2):201-5. PubMed ID: 15865213
[TBL] [Abstract][Full Text] [Related]
37. Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.
Sandoval-Ramirez JL; Mata-Marín JA; Huerta García G; Gaytán-Martínez JE
J Infect Dev Ctries; 2015 Mar; 9(3):267-73. PubMed ID: 25771464
[TBL] [Abstract][Full Text] [Related]
38. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
Fried MW; Hadziyannis SJ
Semin Liver Dis; 2004; 24 Suppl 2():47-54. PubMed ID: 15346246
[TBL] [Abstract][Full Text] [Related]
39. [Successful therapy with pegylated interferon alfa-2a. Hepatitis C patients remain virus-free].
MMW Fortschr Med; 2003 Sep; 145(35-36):56. PubMed ID: 14584218
[No Abstract] [Full Text] [Related]
40. [Pegylated interferon-alpha for the treatment of chronic hepatitis C].
Weis NM; Krarup HB; Skinhøj P
Ugeskr Laeger; 2003 Oct; 165(44):4211-5. PubMed ID: 14621552
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
